Blockchain Registration Transaction Record

Aditxt Launches Clinical Study for Non-Invasive Endometriosis Test

Aditxt subsidiary Pearsanta begins clinical study for blood-based endometriosis test. Non-invasive diagnostic could revolutionize early detection of condition affecting millions of women worldwide.

This development represents a potential breakthrough in women's healthcare that could fundamentally change how endometriosis is diagnosed and managed. Endometriosis affects approximately 10% of women worldwide, with many suffering for years without proper diagnosis due to the invasive nature of current diagnostic methods. The current gold standard requires laparoscopic surgery, which carries risks, costs, and recovery time that often delay diagnosis and treatment. A reliable blood-based test could enable earlier detection, reduce diagnostic delays from the current average of 7-10 years, and allow for timely intervention that could prevent disease progression and preserve fertility. For the millions of women affected by endometriosis, this innovation could mean faster diagnosis, reduced surgical procedures, and improved quality of life through earlier treatment options.